DISPOSITION OF A NEW ANTIINFECTIVE AGENT 1,3-DI(4-IMIDAZOLINO-2-METHOXYPHENOXY)PROPANE IN MALE-RATS

被引:0
作者
BEKERSKY, I
PUHL, RJ
HANSON, G
MONG, S
机构
[1] HAZELTON WISCONSIN INC, DEPT METAB & DISPOSIT, MADISON, WI USA
[2] HAZELTON WISCONSIN INC, DEPT BIOPHARMACEUT, MADISON, WI USA
[3] IMMUNOPHARMACEUT INC, SAN DIEGO, CA USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The disposition of 1,3-di[4-imidazolino-2-methoxyphenoxy]propane (DMP) is described in male rats following a single 2.5 mg/kg intravenous or 16 mg/kg oral administration of DMP . lactate in an aqueous (5% dextrose) solution. Following the intravenous administration, plasma concentrations of DMP declined in an apparent biexponential manner and were nonmeasurable after 24 hr. The mean terminal plasma elimination half-life was 14.9 hr. A volume of distribution of 18.7 liters/kg and a body clearance of 14.5 ml/min/kg were estimated. After oral administration, mean plasma concentrations of DMP reached a maximum of 39.6 ng/ml at 15 min and were non-measurable after 4 hr. The areas under the curve (AUC)0-24 of DMP was 2276 ng . hr/ml following the intravenous dose. The AUC0-4 was 68 ng . hr/ml following the oral dose. The AUC0-4 was 68 ng - hr/ml following the oral dose. Based on a comparison of AUC0-4 the oral bioavailability was 0.9%. A mean of 41.7 and 0.4% of the dose was excreted in urine as DMP following intravenous and oral administration, respectively. The tissue distribution and mass balance of total C-14 were determined following a single 2.5 mg/kg intravenous administration of [C-14]DMP-lactate. The concentrations of total C-14 in all tissues were highest at 0.5 hr and declined with time thereafter. The highest concentration of C-14 was in the kidneys, whereas the highest total amount was in the liver. Decline of C-14 from kidneys and liver was apparently biexponential, whereas it was monoexponential from the lungs. The concentrations and amounts of radioactivity in all other tissues were small by comparison. The combined total amount represented <0.5% of the dose at any given time point. A total of 73.4% of the C-14 dose was excreted in urine (45.7%) and feces (23.2%) in 72 hr. The substantial fecal excretion following intravenous administration suggests that the in vivo disposition of DMP in rats includes biliary excretion.
引用
收藏
页码:1017 / 1021
页数:5
相关论文
共 22 条
  • [1] ADVERSE REACTIONS ASSOCIATED WITH PENTAMIDINE ISETHIONATE IN AIDS PATIENTS - RECOMMENDATIONS FOR MONITORING THERAPY
    ANDERSEN, R
    BOEDICKER, M
    MA, M
    GOLDSTEIN, EJC
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1986, 20 (11): : 862 - 868
  • [2] BERGER BJ, 1991, J PHARMACOL EXP THER, V256, P883
  • [3] COMPARISON OF TISSULAR DISPOSITION OF PENTAMIDINE MESYLATE IN THE RAT AFTER AEROSOL OR PARENTERAL ADMINISTRATION
    FARINOTTI, R
    PASCAUD, MB
    GIRARD, PM
    GUILLOT, E
    CERTAIN, A
    TROUVIN, JH
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (03) : 507 - 512
  • [4] PENTAMIDINE ISETHIONATE - A REVIEW OF ITS ANTIPROTOZOAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN PNEUMOCYSTIS-CARINII PNEUMONIA
    GOA, KL
    CAMPOLIRICHARDS, DM
    [J]. DRUGS, 1987, 33 (03) : 242 - 258
  • [5] HANSON G, IN PRESS J CHROMATOG
  • [6] COMPARISON OF PENTAMIDINE ISETHIONATE AND TRIMETHOPRIM-SULFAMETHOXAZOLE IN TREATMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA
    HUGHES, WT
    FELDMAN, S
    CHAUDHARY, SC
    OSSI, MJ
    COX, F
    SANYAL, SK
    [J]. JOURNAL OF PEDIATRICS, 1978, 92 (02) : 285 - 291
  • [7] NOVEL PENTAMIDINE ANALOGS IN THE TREATMENT OF EXPERIMENTAL PNEUMOCYSTIS-CARINII PNEUMONIA
    JONES, SK
    HALL, JE
    ALLEN, MA
    MORRISON, SD
    OHEMENG, KA
    REDDY, VV
    GERATZ, JD
    TIDWELL, RR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) : 1026 - 1030
  • [8] KAPUSNIK JE, 1988, ANTIMICROBIAL AGENTS, P299
  • [9] ACUTE RESPIRATORY-FAILURE SECONDARY TO PNEUMOCYSTIS-CARINII PNEUMONIA IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME - A POTENTIAL ROLE FOR SYSTEMIC CORTICOSTEROIDS
    MONTANER, JSG
    RUSSELL, JA
    LAWSON, L
    RUEDY, J
    [J]. CHEST, 1989, 95 (04) : 881 - 884
  • [10] MORGAN WM, 1986, PUBLIC HEALTH REP, V101, P459